Immunoediting, the loss of tumor (neo)antigens due to T cell-dependent selection, sculpts tumor immunogenicity. In Nature, Łuksza et al. conceive a model to score neoantigens' immunogenicity and predict tumor clonal evolution. With this model, they demonstrate that durable tumor control associates with selective limited acquisition of high-quality mutations.